Disparities in Access to Sorafenib in Communities with Low Socioeconomic Status | Zendy

Umut Sarpel | Zendy; Marina Heskel | Zendy; John Spivack | Zendy; Yael Feferman | Zendy; Celina Ang | Zendy; Francesca Gany | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Disparities in Access to Sorafenib in Communities with Low Socioeconomic Status

Author(s) -

Umut Sarpel,

Marina Heskel,

John Spivack,

Yael Feferman,

Celina Ang,

Francesca Gany

Publication year - 2018

Publication title -

journal of health care for the poor and underserved

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.511

H-Index - 59

eISSN - 1548-6869

pISSN - 1049-2089

DOI - 10.1353/hpu.2018.0083

Subject(s) - socioeconomic status , residence , medicine , sorafenib , medical prescription , demography , ethnic group , odds , odds ratio , hepatocellular carcinoma , environmental health , gerontology , logistic regression , population , political science , sociology , law , pharmacology

In the United States, hepatocellular carcinoma (HCC) is more common among communities with low socioeconomic status (SES), and these groups tend to be diagnosed with later-stage cancers. Sorafenib is the primary treatment for advanced HCC, however its substantial cost raises concern for access to treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research